| For: | Neureiter D, Jäger T, Ocker M, Kiesslich T. Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects. World J Gastroenterol 2014; 20(24): 7830-7848 [PMID: 24976721 DOI: 10.3748/wjg.v20.i24.7830] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i24/7830.htm |
| Number | Citing Articles |
| 1 |
Sena Şen, Merve Çiğdem Özgel, Şeref Buğra Tunçer, Hamza Uğur Bozbey, Senem Karabulut, Didem Taştekin. A Pilot Study of Exploring miRNA–Protein Interaction Networks in Pancreatic Ductal Adenocarcinoma Patients: Implications for Diagnosis and Prognosis. Diagnostics 2025; 15(19) doi: 10.3390/diagnostics15192479
|
| 2 |
Qiangsheng Hu, Yi Qin, Shunrong Ji, Wenyan Xu, Wensheng Liu, Qiqing Sun, Zheng Zhang, Mengqi Liu, Quanxing Ni, Xianjun Yu, Xiaowu Xu. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Cancer Letters 2019; 452 doi: 10.1016/j.canlet.2019.03.024
|
| 3 |
Elisabeth Hessmann, Steven A Johnsen, Jens T Siveke, Volker Ellenrieder. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?. Gut 2017; 66(1) doi: 10.1136/gutjnl-2016-312539
|
| 4 |
Kai Hayashi, Yicong Huang, Kenneth R Muir, Artitaya Lophatananon. Epigenetic mechanisms linking hexavalent chromium exposure to pancreatic cancer risk: a systematic review. Environmental Epigenetics 2026; 12(1) doi: 10.1093/eep/dvag013
|
| 5 |
Xiaoli Yin, Lingming Kong, Peng Liu. Identification of prognosis-related molecular subgroups based on DNA methylation in pancreatic cancer. Clinical Epigenetics 2021; 13(1) doi: 10.1186/s13148-021-01090-w
|
| 6 |
Michael Olivier, Reto Asmis, Gregory A. Hawkins, Timothy D. Howard, Laura A. Cox. The Need for Multi-Omics Biomarker Signatures in Precision Medicine. International Journal of Molecular Sciences 2019; 20(19) doi: 10.3390/ijms20194781
|
| 7 |
Raúl Ortíz, Francisco Quiñonero, Beatriz García-Pinel, Marco Fuel, Cristina Mesas, Laura Cabeza, Consolación Melguizo, Jose Prados. Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress. Cancers 2021; 13(9) doi: 10.3390/cancers13092058
|
| 8 |
Dietrich A. Ruess, Kivanc Görgülü, Sonja M. Wörmann, Hana Algül. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs & Aging 2017; 34(5) doi: 10.1007/s40266-017-0453-y
|
| 9 |
Ainhoa Mielgo, Michael C. Schmid. Liver Tropism in Cancer: The Hepatic Metastatic Niche. Cold Spring Harbor Perspectives in Medicine 2020; 10(3) doi: 10.1101/cshperspect.a037259
|
| 10 |
Myrna Hurtado, Umesh T. Sankpal, Amalendu Ranjan, Rajasekhar Maram, Jamboor K. Vishwanatha, Ganji Purnachandra Nagaraju, Bassel F. El-Rayes, Riyaz Basha. Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. Critical Reviews in Oncology/Hematology 2018; 126 doi: 10.1016/j.critrevonc.2018.03.016
|
| 11 |
Sona Ciernikova, Julie Earl, María Laura García Bermejo, Viola Stevurkova, Alfredo Carrato, Bozena Smolkova. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?. International Journal of Molecular Sciences 2020; 21(11) doi: 10.3390/ijms21114091
|
| 12 |
Subhashini Brahadeeswaran, Suchitra Sreedhar, Srinithy Ramesh, Ramasamy Tamizhselvi. Targeting ferroptosis mediated cell death: a novel strategy for mitigating acute pancreatitis. Molecular Biology Reports 2026; 53(1) doi: 10.1007/s11033-026-11772-4
|
| 13 |
Abilash Navaneethan, Mrithika Ajay, Karnika Yogeswari Makesh, Ganesh Munuswamy-Ramanujam, Rameshbabu Boga, Dhanavathy Gnanasampanthapandian, Kanagaraj Palaniyandi. Exploring the Role of Histone Lysine Methyl Transferases in Pancreatic Cancer: A Review of Therapeutics and Clinical Implications. Journal of Endocrinology and Reproduction 2025; doi: 10.18311/jer/2024/49088
|
| 14 |
Feda H. Hamdan, Steven A. Johnsen. Epigenetic Targeting of Aberrant Transcriptional Modulation in Pancreatic Cancer. Epigenomes 2018; 2(2) doi: 10.3390/epigenomes2020008
|
| 15 |
P. A. Ávila-López, G. Guerrero, H. N. Nuñez-Martínez, C. A. Peralta-Alvarez, G. Hernández-Montes, L. G. Álvarez-Hilario, R. Herrera-Goepfert, J. Albores-Saavedra, N. Villegas-Sepúlveda, L. Cedillo-Barrón, A. E. Montes-Gómez, M. Vargas, M. Schnoor, F. Recillas-Targa, R. Hernández-Rivas. H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma. Oncogene 2021; 40(11) doi: 10.1038/s41388-021-01664-1
|
| 16 |
Brittany Silverman, Jiaqi Shi. Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications. International Journal of Molecular Sciences 2016; 17(12) doi: 10.3390/ijms17122138
|
| 17 |
Uroš Gašić, Ivanka Ćirić, Tomislav Pejčić, Dejan Radenković, Vladimir Djordjević, Siniša Radulović, Živoslav Tešić. Polyphenols as Possible Agents for Pancreatic Diseases. Antioxidants 2020; 9(6) doi: 10.3390/antiox9060547
|
| 18 |
Yishuo Wang, Zhongyong Liu, Qinrong Liu, Yongguang Han, Yuncai Zang, Huichao Zhang, Xuzhao Du, Tao Qin, Yuquan Wu. <p>Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis</p>. Cancer Management and Research 2020; doi: 10.2147/CMAR.S237323
|
| 19 |
Afsaneh Barzi, Rebecca Miksad, Andy Surinach, Frank A. Corvino, Siqi Wang, Aracelis Z. Torres, Khalid Mamlouk, Sonia Pulgar, Adriana Valderrama, Tanios Bekaii-Saab, Daniel Ahn. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Pancreas 2020; 49(2) doi: 10.1097/MPA.0000000000001479
|
| 20 |
Ti-Dong Shan, Ji-Hao Xu, Tao Yu, Jie-Yao Li, Lin-Na Zhao, Hui Ouyang, Su Luo, Xi-Ji Lu, Can-Ze Huang, Qiu-Shen Lan, Wa Zhong, Qi-Kui Chen. Knockdown of linc-POU3F3 suppresses the proliferation, apoptosis, and migration resistance of colorectal cancer. Oncotarget 2016; 7(1) doi: 10.18632/oncotarget.5830
|
| 21 |
Bo Tang, Yang Li, Guangying Qi, Shengguang Yuan, Zhenran Wang, Shuiping Yu, Bo Li, Songqing He. Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer. Scientific Reports 2015; 5(1) doi: 10.1038/srep13563
|
| 22 |
Fatima Khan, Shariq Ahmed, Uzma Tayyaba. Human Microbiome and their Implications for Oncological Diagnosis and Treatment. 2026; doi: 10.1016/B978-0-443-40551-8.00005-6
|
| 23 |
E. A. Bykova, N. A. Falaleeva, L. Yu. Grivtsova. PANCREATIC CANCER, CURRENT THERAPEUTIC APPROACHES AND POSSIBLE PROSPECTS. Russian Journal of Biotherapy 2020; 19(4) doi: 10.17650/1726-9784-2020-19-4-18-28
|
| 24 |
Brooke D. Paradise, Whitney Barham, Martín E. Fernandez-Zapico. Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes?. Cancers 2018; 10(5) doi: 10.3390/cancers10050128
|
| 25 |
Masoumeh Kiani-Zadeh, Mohammad Reza Rezvany, Soodeh Namjoo, Mahmood Barati, Mohammad Hossein Mohammadi, Bahare Ghasemi, Tahere Tabatabaei, Ardeshir Ghavamzadeh, Farhad Zaker, Ladan Teimoori-Toolabi. Studying the potential of upregulated PTGS2 and VEGF-C besides hyper-methylation of PTGS2 promoter as biomarkers of Acute myeloid leukemia. Molecular Biology Reports 2022; 49(8) doi: 10.1007/s11033-022-07615-7
|
| 26 |
Mansunderbir Singh, Priyanka Anvekar, Bhavana Baraskar, Namratha Pallipamu, Srikanth Gadam, Akhila Sai Sree Cherukuri, Devanshi N. Damani, Kanchan Kulkarni, Shivaram P. Arunachalam. Prospective of Pancreatic Cancer Diagnosis Using Cardiac Sensing. Journal of Imaging 2023; 9(8) doi: 10.3390/jimaging9080149
|
| 27 |
Kelly Foley, Victoria Kim, Elizabeth Jaffee, Lei Zheng. Current progress in immunotherapy for pancreatic cancer. Cancer Letters 2016; 381(1) doi: 10.1016/j.canlet.2015.12.020
|
| 28 |
Verónica del Carmen Martínez‐Jiménez, Alejandro Méndez‐Mancilla, Diana Patricia Portales‐Pérez. miRNAs in nutrition, obesity, and cancer: The biology of miRNAs in metabolic disorders and its relationship with cancer development. Molecular Nutrition & Food Research 2018; 62(1) doi: 10.1002/mnfr.201600994
|
| 29 |
Junya Peng, Bao-Fa Sun, Chuan-Yuan Chen, Jia-Yi Zhou, Yu-Sheng Chen, Hao Chen, Lulu Liu, Dan Huang, Jialin Jiang, Guan-Shen Cui, Ying Yang, Wenze Wang, Dan Guo, Menghua Dai, Junchao Guo, Taiping Zhang, Quan Liao, Yi Liu, Yong-Liang Zhao, Da-Li Han, Yupei Zhao, Yun-Gui Yang, Wenming Wu. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Research 2019; 29(9) doi: 10.1038/s41422-019-0195-y
|
| 30 |
Sara Asgharzadeh, Farzaneh Tafvizi, Vahid Chaleshi, Shahrokh Iravani. Lack of association between LincRNA-Pou3f gene expression and clinicopathological features in gastric cancer tissue. Gene Reports 2020; 20 doi: 10.1016/j.genrep.2020.100700
|
| 31 |
Anna-Laura Kretz, Silvia Von Karstedt, Andreas Hillenbrand, Doris Henne-Bruns, Uwe Knippschild, Anna Trauzold, Johannes Lemke. Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. Cancers 2018; 10(3) doi: 10.3390/cancers10030077
|
| 32 |
Hua Liu, Xuan-Fu Xu, Yan Zhao, Mao-Chun Tang, Ying-Qun Zhou, Jie Lu, Feng-Hou Gao. MicroRNA-191 promotes pancreatic cancer progression by targeting USP10. Tumor Biology 2014; 35(12) doi: 10.1007/s13277-014-2521-9
|
| 33 |
Caiting Yang, Peike Peng, Lili Li, Miaomiao Shao, Junjie Zhao, Lan Wang, Fangfang Duan, Shushu Song, Hao Wu, Jie Zhang, Ran Zhao, Dongwei Jia, Mingming Zhang, Weicheng Wu, Can Li, Yefei Rong, Lei Zhang, Yuanyuan Ruan, Jianxin Gu. High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer. Scientific Reports 2016; 6(1) doi: 10.1038/srep39044
|
| 34 |
Giovanni Colonna. Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions. Cancers 2025; 17(13) doi: 10.3390/cancers17132102
|
| 35 |
Max M. Träger, Sameer A. Dhayat. Epigenetics of epithelial‐to‐mesenchymal transition in pancreatic carcinoma. International Journal of Cancer 2017; 141(1) doi: 10.1002/ijc.30626
|
| 36 |
Monika Bauden, Dorian Pamart, Daniel Ansari, Marielle Herzog, Mark Eccleston, Jake Micallef, Bodil Andersson, Roland Andersson. Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clinical Epigenetics 2015; 7(1) doi: 10.1186/s13148-015-0139-4
|
| 37 |
Kathy A. Gelato, David Adler, Matthias Ocker, Bernard Haendler. Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs. Expert Opinion on Therapeutic Targets 2016; 20(7) doi: 10.1517/14728222.2016.1134490
|
| 38 |
Zhao-Chun Chi. Research status and prgoress of nonalcoholic fatty pancreatic disease. World Chinese Journal of Digestology 2020; 28(19) doi: 10.11569/wcjd.v28.i19.933
|
| 39 |
Jae-Seok Roe, Chang-Il Hwang, Tim D.D. Somerville, Joseph P. Milazzo, Eun Jung Lee, Brandon Da Silva, Laura Maiorino, Hervé Tiriac, C. Megan Young, Koji Miyabayashi, Dea Filippini, Brianna Creighton, Richard A. Burkhart, Jonathan M. Buscaglia, Edward J. Kim, Jean L. Grem, Audrey J. Lazenby, James A. Grunkemeyer, Michael A. Hollingsworth, Paul M. Grandgenett, Mikala Egeblad, Youngkyu Park, David A. Tuveson, Christopher R. Vakoc. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell 2017; 170(5) doi: 10.1016/j.cell.2017.07.007
|
| 40 |
Sung Hwan Cho, Mihyang Ha, Yong Hoon Cho, Je Ho Ryu, Kwangho Yang, Kang Ho Lee, Myoung-Eun Han, Sae-Ock Oh, Yun Hak Kim. ALKBH5gene is a novel biomarker that predicts the prognosis of pancreatic cancer: A retrospective multicohort study. Annals of Hepato-Biliary-Pancreatic Surgery 2018; 22(4) doi: 10.14701/ahbps.2018.22.4.305
|
| 41 |
Ti‐Dong Shan, Zi‐Bin Tian, Qian Li, Yue‐ Ping Jiang, Fu‐Guo Liu, Xue‐Guo Sun, Yue Han, Li‐Juan Sun, Li Chen. Long intergenic noncoding RNA 00908 promotes proliferation and inhibits apoptosis of colorectal cancer cells by regulating KLF5 expression. Journal of Cellular Physiology 2021; 236(2) doi: 10.1002/jcp.29899
|
| 42 |
Huiming Chen, Yan Kong, Qing Yao, Xing Zhang, Yunong Fu, Jia Li, Chang Liu, Zheng Wang. Three hypomethylated genes were associated with poor overall survival in pancreatic cancer patients. Aging 2019; 11(3) doi: 10.18632/aging.101785
|
| 43 |
Monika Bauden, Helena Tassidis, Daniel Ansari. In vitro cytotoxicity evaluation of HDAC inhibitor Apicidin in pancreatic carcinoma cells subsequent time and dose dependent treatment. Toxicology Letters 2015; 236(1) doi: 10.1016/j.toxlet.2015.03.017
|
| 44 |
Rituraj Chakraborty, Anupam Dutta, Bhargab Jyoti Baruah, Rajni Kumari, Priyanku Sarma, Ankita Sharma, Krishangi Goswami, Haritha Myakala, Akalesh Kumar Verma. Pancreatic Cancer: A Review on Pathophysiology, Naturopathy, Clinical Treatment and Outcomes. Current Cancer Therapy Reviews 2024; 20(3) doi: 10.2174/1573394719666230830125213
|
| 45 |
Fengjin Zhao, Tianxin Lin, Wang He, Jinli Han, Dingjun Zhu, Kaishun Hu, Weicong Li, Zaosong Zheng, Jian Huang, Wenlian Xie. Knockdown of a novel lincRNA AATBC suppresses proliferation and induces apoptosis in bladder cancer. Oncotarget 2015; 6(2) doi: 10.18632/oncotarget.2833
|
| 46 |
Shan Jiang, Johan Bourghardt Fagman, Yunyun Ma, Jian Liu, Caroline Vihav, Cecilia Engstrom, Beidong Liu, Changyan Chen. A comprehensive review of pancreatic cancer and its therapeutic challenges. Aging 2022; 14(18) doi: 10.18632/aging.204310
|
| 47 |
Roseane Guimarães Ferreira, Luis Eduardo Mosquera Narvaez, Kaio Murilo Monteiro Espíndola, Amanda Caroline R. S. Rosario, Wenddy Graziela N. Lima, Marta Chagas Monteiro. Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer?. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.594917
|
| 48 |
Shin-Heng Chiou, Madeleine Dorsch, Eva Kusch, Santiago Naranjo, Margaret M. Kozak, Albert C. Koong, Monte M. Winslow, Barbara M. Grüner. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-32159-x
|
| 49 |
Peng Xia, Pan Liu, Qiang Fu, Chuanjiang Liu, Qiankun Luo, Xu Zhang, Liyou Cheng, Tao Qin, Hongwei Zhang. Long noncoding RNA EPIC1 interacts with YAP1 to regulate the cell cycle and promote the growth of pancreatic cancer cells. Biochemical and Biophysical Research Communications 2020; 522(4) doi: 10.1016/j.bbrc.2019.11.167
|
| 50 |
Ting Zhang, Linglin Zhao, Shengyuan Zeng, Lu Bai, Junxia Chen, Zheng Zhang, Yalan Wang, Changzhu Duan. UHRF2 decreases H3K9ac expression by interacting with it through the PHD and SRA/YDG domain in HepG2 hepatocellular carcinoma cells. International Journal of Molecular Medicine 2017; 39(1) doi: 10.3892/ijmm.2016.2805
|
| 51 |
Inês Faleiro, Vânia Palma Roberto, Secil Demirkol Canli, Nicolas A. Fraunhoffer, Juan Iovanna, Ali Osmay Gure, Wolfgang Link, Pedro Castelo-Branco. DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study. Cancers 2021; 13(24) doi: 10.3390/cancers13246354
|
| 52 |
Pascal Syren, Roland Andersson, Monika Bauden, Daniel Ansari. Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma. Scandinavian Journal of Gastroenterology 2017; 52(6-7) doi: 10.1080/00365521.2017.1301989
|
| 53 |
Xin Jiang, Xuyu Chen, Jianlei Xia, Bengang Zhou, Aiping Zhang, Yuanyuan Chen, Qiang She, Yaoyao Li, Yanbing Ding, Min Zhang. MAFF drives pancreatic cancer progression through AKR1C1-mediated inhibition of ferroptosis. QJM: An International Journal of Medicine 2026; 119(4) doi: 10.1093/qjmed/hcaf272
|
| 54 |
Zhiming Zhao, Mengyang Li, Xianglong Tan, Dabin Xu, Rong Liu. Methylation Patterns Partition Pancreatic Cancer into Distinct Prognostic Subtypes. Future Oncology 2021; 17(16) doi: 10.2217/fon-2020-0804
|
| 55 |
Liu Yang, Yinan Zhang, Jun Bao, Ji-Feng Feng. Long non-coding RNA BCYRN1 exerts an oncogenic role in colorectal cancer by regulating the miR-204-3p/KRAS axis. Cancer Cell International 2020; 20(1) doi: 10.1186/s12935-020-01543-x
|
| 56 |
Andee Weisbeck, Rick Jansen. Nutrients and the Pancreas: An Epigenetic Perspective. Nutrients 2017; 9(3) doi: 10.3390/nu9030283
|
| 57 |
Gang Ning, Yongqiang Li, Wenji Chen, Wenjuan Tang, Diwen Shou, Qingling Luo, Huiting Chen, Yongjian Zhou, Reem Saleh. CpG Island Methylator Phenotype Modulates the Immune Response of the Tumor Microenvironment and Influences the Prognosis of Pancreatic Cancer Patients. Journal of Oncology 2021; 2021 doi: 10.1155/2021/2715694
|
| 58 |
Prakash Chaudhary, Diwakar Guragain, Jae-Hoon Chang, Jung-Ae Kim. TPH1 and 5-HT7 Receptor Overexpression Leading to Gemcitabine-Resistance Requires Non-Canonical Permissive Action of EZH2 in Pancreatic Ductal Adenocarcinoma. Cancers 2021; 13(21) doi: 10.3390/cancers13215305
|
| 59 |
T Yu, T-D Shan, J-Y Li, C-Z Huang, S-Y Wang, H Ouyang, X-J Lu, J-H Xu, W Zhong, Q-K Chen. Knockdown of linc-UFC1 suppresses proliferation and induces apoptosis of colorectal cancer. Cell Death & Disease 2016; 7(5) doi: 10.1038/cddis.2016.124
|
| 60 |
Juan Pablo Arnoletti, Xiang Zhu, Alvin J.O. Almodovar, Paula P. Veldhuis, Ryan Sause, Elizabeth Griffith, George Corpus, Jeffrey C.C. Chang, Na'im Fanaian, Sally A. Litherland. Portal Venous Blood Circulation Supports Immunosuppressive Environment and Pancreatic Cancer Circulating Tumor Cell Activation. Pancreas 2017; 46(1) doi: 10.1097/MPA.0000000000000667
|
| 61 |
Marina Ayres Pereira, Iok In Christine Chio. Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies. Genes 2019; 11(1) doi: 10.3390/genes11010006
|
| 62 |
Kai Xu, Zainab Motiwala, Irene Corona-Avila, Dhruvi Makhanasa, Leen Alkahalifeh, Md. Wasim Khan. The Gut Microbiome and Its Multifaceted Role in Cancer Metabolism, Initiation, and Progression: Insights and Therapeutic Implications. Technology in Cancer Research & Treatment 2025; 24 doi: 10.1177/15330338251331960
|
| 63 |
Emily Chan, E. Gabriela Chiorean, Peter J. O’Dwyer, Nashat Y. Gabrail, Thierry Alcindor, Diane Potvin, Richard Chao, Herbert Hurwitz. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Cancer Chemotherapy and Pharmacology 2018; 81(2) doi: 10.1007/s00280-017-3494-3
|
| 64 |
Marwa Elsayed, Maen Abdelrahim. The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. Biomedicines 2021; 9(4) doi: 10.3390/biomedicines9040389
|
| 65 |
Nitish Kumar Mishra, Siddesh Southekal, Chittibabu Guda. Survival Analysis of Multi-Omics Data Identifies Potential Prognostic Markers of Pancreatic Ductal Adenocarcinoma. Frontiers in Genetics 2019; 10 doi: 10.3389/fgene.2019.00624
|
| 66 |
M.J. Lamberti, R.E. Vera, N.B. Rumie Vittar, G. Schneider. Chromatin Signaling and Diseases. 2016; doi: 10.1016/B978-0-12-802389-1.00009-5
|
| 67 |
Rahul R. Singh, Katie M. Reindl, Rick J. Jansen. Epigenomics of Pancreatic Cancer: A Critical Role for Epigenome-Wide Studies. Epigenomes 2019; 3(1) doi: 10.3390/epigenomes3010005
|
| 68 |
|
| 69 |
Rong Tang, Yiyin Zhang, Chen Liang, Jin Xu, Qingcai Meng, Jie Hua, Jiang Liu, Bo Zhang, Xianjun Yu, Si Shi. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. PeerJ 2020; 8 doi: 10.7717/peerj.9602
|
| 70 |
Akash Bararia, Amlan Das, Sangeeta Mitra, Sudeep Banerjee, Aniruddha Chatterjee, Nilabja Sikdar. Deoxyribonucleic acid methylation driven aberrations in pancreatic cancer-related pathways. World Journal of Gastrointestinal Oncology 2023; 15(9): 1505-1519 doi: 10.4251/wjgo.v15.i9.1505
Abstract(1041) |
Core Tip(978) |
Full Article(HTML)(4281)
|
Full Article (PDF)-2009K(279)
|
Full Article with Cover (PDF)-2302K(287)
|
Full Article (Word)-641K(91)
|
Full Article (XML)-278K(184)
|
Audio-449K(19)
|
Peer-Review Report-207K(181)
|
Answering Reviewers-146K(177)
|
Times Cited (7)
|
Total Visits (6369)
|
Open
|
| 71 |
Sanjay Kumar, Rajesh Singh, Manoj K. Mishra. Epigenetic Mechanisms in Cancer. 2018; doi: 10.1016/B978-0-12-809552-2.00005-X
|
| 72 |
Manoj Kumar Gupta, Ramakrishna Vadde. Immune Landscape of Pancreatic Cancer Development and Drug Resistance. 2024; doi: 10.1016/B978-0-443-23523-8.00004-3
|
| 73 |
Hironori Hayashi, Koji Amaya, Tomokazu Tokoro, Kosuke Mori, Shunsuke Takenaka, Yuya Sugimoto, Yuto Kitano, Toru Kurata, Shunsuke Kawai, Atsushi Hirose, Tomoya Tsukada, Masahide Kaji, Koichi Shimizu, Kiichi Maeda. Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis. Molecular and Clinical Oncology 2021; 15(3) doi: 10.3892/mco.2021.2335
|
| 74 |
Claudia C. Preston, Randolph S. Faustino. Nuclear Envelope Regulation of Oncogenic Processes: Roles in Pancreatic Cancer. Epigenomes 2018; 2(3) doi: 10.3390/epigenomes2030015
|
| 75 |
Zheng Lu, Zheng-Quan Lai, Albert W.N. Leung, Po Sing Leung, Zhao-Shen Li, Zhi-Xiu Lin. Exploring brusatol as a new anti-pancreatic cancer adjuvant: biological evaluation and mechanistic studies. Oncotarget 2017; 8(49) doi: 10.18632/oncotarget.17761
|
| 76 |
David E. Amacher. A 2015 survey of established or potential epigenetic biomarkers for the accurate detection of human cancers. Biomarkers 2016; 21(5) doi: 10.3109/1354750X.2016.1153724
|
| 77 |
|
| 78 |
Xiao Yu, Yun Wang, Xiaoyi Shi, Zhihui Wang, Peihao Wen, Yuting He, Wenzhi Guo. Dysfunctional epigenetic protein-coding gene-related signature is associated with the prognosis of pancreatic cancer based on histone modification and transcriptome analysis. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-022-27316-2
|
| 79 |
Asaad Azarnezhad, Parvin Mehdipour. Cancer Genetics and Psychotherapy. 2017; doi: 10.1007/978-3-319-64550-6_5
|
| 80 |
Ting He, Fangli Zhou, Anping Su, Yujie Zhang, Zhichao Xing, Li Mi, Zhihui Li, Wenshuang Wu. Brusatol: A potential sensitizing agent for cancer therapy from Brucea javanica. Biomedicine & Pharmacotherapy 2023; 158 doi: 10.1016/j.biopha.2022.114134
|